The AK1 Knockout HAP1 Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal knockout population targeting the AK1 gene within the HAP1 human near-haploid cell line. This loss-of-function model is generated through targeted gene disruption of the adenylate kinase 1 locus, resulting in abrogation of AK1 protein expression and enzymatic activity. The polyclonal cell population retains the genetic heterogeneity typical of pooled knockout derivatives, providing a robust tool for functional genomics, pathway analysis, and phenotypic screening without the constraints of clonal selection.
The HAP1 cell line is a human near-haploid chronic myeloid leukemia model derived from the KBM-7 blast crisis cell line. It maintains a near-haploid karyotype, with disomy limited to chromosome 15, a feature that simplifies genetic manipulation and facilitates unambiguous genotype-phenotype correlation. Widely employed as a genetic screening platform and leukemia biology model, HAP1 cells enable efficient knockout generation and high-throughput functional assays, making them ideally suited for dissecting gene function in a leukemic context.
AK1 encodes adenylate kinase 1, a key enzyme that catalyzes the reversible phosphotransfer reaction ATP + AMP ? 2 ADP, central to maintaining cellular adenylate energy charge and regulating AMP/ATP ratios. AK1 activity is modulated by upstream cues including the AMP/ATP ratio, oxidative stress, and hypoxia. Through its influence on adenine nucleotide pools, AK1 directly governs the activation state of AMP-activated protein kinase (AMPK), a critical energy sensor. Mechanistically, under energy stress, elevated AMP levels promote AMPK phosphorylation at Thr172 by upstream kinases such as LKB1. Activated AMPK phosphorylates downstream targets including TSC2 and mTOR, thereby coordinating metabolic responses. Additionally, AK1 intersects with purine nucleotide metabolism and mitochondrial respiration, and although it lacks well-characterized protein binding partners beyond its substrates ATP, AMP, and ADP, it functions within a network with other adenylate kinase family members like AK2 and AK3.
In the HAP1 leukemic background, disruption of AK1 profoundly impacts cellular energy homeostasis and nucleotide metabolism. This knockout model is particularly valuable for investigating metabolic vulnerabilities in leukemia, where dysregulated energy sensing and an altered AMPK signaling axis are increasingly recognized as therapeutic targets. The near-haploid nature of HAP1 permits clean dissection of AK1-dependent phenotypes, such as altered sensitivity to glucose deprivation or oxidative stress. The model also provides a relevant platform for studying adenylate kinase deficiency and related hemolytic anemias, as well as broader metabolic syndrome contexts, while offering insights into how leukemic cells may circumvent energy crisis.
Researchers can employ this polyclonal knockout product for a wide range of applications. These include detailed studies of cellular energy homeostasis, nucleotide metabolism, functional genetics, and high-throughput drug screening for metabolic inhibitors. Representative experimental readouts encompass western blotting for phospho-AMPK (Thr172) to assess AMPK pathway activation, AMP/ATP quantification assays using luminescence-based methods, metabolic flux analysis via Seahorse or isotopologue tracing, cell viability assays under glucose deprivation, nucleotide profiling by HPLC or mass spectrometry, and drug sensitivity testing with agents such as metformin. This model thus supports both hypothesis-driven research and screening campaigns in leukemia biology and beyond. For further information, please contact Ascent Research.
